New Stock News | Aihang Biotechnology's Hong Kong IPO and domestic unlisted shares' "full circulation" have been filed with the China Securities Regulatory Commission.

On August 28, the International Cooperation Department of the China Securities Regulatory Commission issued a "Notification on the Filing for the Overseas Issuance and Listing of Suzhou Yinhang Biotechnology Co., Ltd. and the 'Full Circulation' of Its Unlisted Shares in the Domestic Market." The company plans to issue no more than 18,271,600 shares of overseas listed common stock and list them on the Hong Kong Stock Exchange. The company's 27 shareholders intend to convert a total of 47,665,277 shares of unlisted domestic stock into overseas listed shares for circulation on the Hong Kong Stock Exchange. The prospectus shows that Yinhang Biotechnology is a leader in synthetic biology driven by technological innovation, dedicated to providing green, sustainable, and efficient production of bio-based products with significant cost advantages. The company's products have already established a leading position in the relevant market. In terms of active pharmaceutical ingredients and intermediates, according to Frost & Sullivan, following the realization of large-scale production of florfenicol by 2025, the company's market share for the nine months ending September 30, 2025, is projected to be 24.5%, ranking second in the global florfenicol industry; calculated based on income for the nine months ending September 30, 2025 (including internal and external sales), the company's D-Ethyl market share is 44.5%, ranking first in the global D-Ethyl industry.